| Business Summary | | Cepheid,
Inc.
develops
new
technology
platforms
that
exploit
the
advantages
of
micromachining,
microelectronics
and
microfluidic
technologies
to
create
automated,
integrated,
miniaturized
instrument
systems
for
life
sciences
research,
clinical
diagnostics,
industrial
testing
and
pharmacogenomics
markets.
Through
March
31,
2000,
the
Company
was
considered
to
be
in
the
development
stage.
During
May
2000,
Cepheid
launched
its
first
product,
the
Smart
Cycler,
through
a
distributor
in
the
United
States
and
recognized
revenue
from
product
sales. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cepheid,
Inc.
develops,
manufactures
and
markets
microfluidic
systems
that
integrate,
automate
and
accelerate
biological
testing.
For
the
six
months
ended
6/30/01,
revenues
totalled
$5.4
million,
up
from
$2.1
million.
Net
loss
applicable
to
Common
fell
73%
to
$7.3
million.
Revenues
reflect
an
increase
in
product
sales
and
the
inclusion
of
Smart
Cycler
sales.
Lower
loss
reflects
the
absence
of
$19.1
million
in
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Thomas Gutshall, 63 Chairman,
CEO | $235K | -- | Kurt Petersen, Ph.D., 53 Pres,
COO, Director | 198K | -- | Catherine Smith, 45 CFO,
VP-Fin. | 166K | $45K | M. Allen Northrup, Ph.D., 46 VP-
Research, CTO | 231K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|